IO BIOTECH, INC.
IO BIOTECH develops treatments for solid tumors and other diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IO Biotech's stock with a target price of $2.46, indicating potential growth.
Financial Health
IO Biotech is managing to generate cash flow, but its book value per share is quite low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IOBT
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalyst-driven stock
Clinical trial results and regulatory milestones can sharply move valuation; outcomes are binary and volatility is common.
Therapy development focus
Progress in clinical data may open partnership or licensing opportunities, though development setbacks and delays are possible.
Industry context
Operates in a competitive oncology landscape where funding, regulation and rival programmes shape prospects; consider liquidity and dilution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
